2006 AFRRI Seminars

Jump to: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003

Venue

Time: 11 a.m. to 12 noon (unless otherwise noted) each Friday
Place: AFRRI Conference Room, unless otherwise indicated.

Directions to AFRRI | Base map | Security, base access, parking

Seminars are presented by AFRRI researchers and other members of the scientific community. While some seminars are open to the public, others are limited to specific audiences. Any exceptions to time, place, and admittance are noted with each item. We do not record or distribute information presented in our Seminar Program. However, where available, references to related information are provided with the seminar title.

2006 seminar schedule

Friday, December 15: Elena Feinstein, MD, PhD, Vice President, R&D, Cleveland Biolabs Inc., Cleveland, Ohio: Radioprotective properties of TLR5 and TLR2 agonists. Related information:
- Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem. 281:3810–3820, 2006.
- p53 is a suppressor of inflammatory response in mice. FASEB J., 19:1030–1032, 2005.
- Ral-GTPases: good chances for a long-lasting fame. Oncogene. 24:326–328, 2005.
Friday, December 1: Richard G. Sedlak, COL, USA, OIC-Medical Radiological Advisory Team, AFRRI: Acute radiation syndrome, Part II (MEIR Course).
Thursday, November 16: Thomas M. Seed, PhD, Associate Chief of Research, Radiation Effects Research Foundation, Minami-ku, Hiroshima 732-0815, Japan: Radiation effects research foundation: Some thoughts on the organization and it's science. Related information:
- Radiation protectants: current status and future prospects. Health Phys. 89:531–545, 2005.
- Radioprotectors: current status and new directions. Radiat Res. 163:704–705, 2005.
- Hematopoietic responses under protracted exposures to low daily dose gamma irradiation. Adv Space Res. 30:945–955, 2002.
Thursday, November 9: Kazuo Neriishi, MD, PhD, Assistant Chief, Department of Clinical Studies, Radiation Effects Research Foundation, Minami-Ku, Hiroshima, Japan: Seven year follow-up of Tokaimura residents after criticality accident. Related information:
- Cataract in atomic bomb survivors. Int J Radiat Biol. 80:339–345, 2004.
- Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. Br J Haematol. 121:405–410, 2003.
- Persistent subclinical inflammation among A-bomb survivors. Int J Radiat Biol. 77:475–482, 2001.
Friday, November 3: S. Srivastava, PhD, Co-Director and Scientific Director, Center for Prostate Disease Research (CPDR), Department of Surgery, USUHS: ETS related gene (ERG) alteration: A common feature of the prostate cancer genome. Related information:
- Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene. 25:3905–3913, 2006.
- Frequent over expression of ETS related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 24:3847–3852, 2005.
- Elevated expression of PCGEM1, a prostate-specific gene with cell growth promoting function, is associated with high-risk prostate cancer patients. Oncogene. 23:605–611, 2004.
Friday, October 27: Marcy B. Grace, PhD, Biological Dosimetry Group, AFRRI: Portrait of transcriptional responses to ionizing radiation and radiomodifiers. Related information:
- Human in vivo radiation-induced biomarkers:gene expression changes in radiotherapy patients. Cancer Res. 64:6368–6371, 2004.
- Development and assessment of a quantitative reverse transcription-PCR assay for simultaneous measurement of four amplicons. Clin Chem. 49:1467–1475, 2003.
- Real-time quantitative RT-PCR assay of GADD45 gene expression changes as a biomarker for radiation biodosimetry. Int J Radiat Biol. 78:1011–1021, 2002.
Friday, October 20: Pataje G.S. Prasanna, PhD, Research Biologist, Biological Dosimetry Program, AFRRI: Cytogenetic laboratory automation, laboratory information management system, and inter-laboratory comparison of the dicentric assay for radiation dose assessment. Related information:
- Early-response biological dosimetry—recommended countermeasure enhancements for mass-casualty radiological incidents and terrorism. Health Phys. 89:494–504, 2005.
- Premature chromosome condensation in human resting peripheral blood lymphocytes for chromosome aberration analysis using specific whole-chromosome DNA hybridization probes. Methods Mol Biol. 291:49–57, 2005.
- Radiation biodosimetry: applications for spaceflight. Adv Space Res. 31:1487–1493, 2003.
Friday, October 13: Mark H. Whitnall, PhD, Program Advisor, Radiation Countermeasures Program, AFRRI: Acute radiation syndrome—Countermeasures. Related information:
- Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. Immunopharmacol Immunotoxicol. 27:521–534, 2005.
- Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharmacol Immunotoxicol. 24:595–626, 2002.
- In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. Radiat Res. 156:283–293, 2001.
Friday, October 6: William E. Dickerson, MD, Colonel, USAF, MC, Director, Military Medical Operations, AFRRI: Management of internal radionuclide contamination (MEIR). Related information:
- Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 140:1037–1051, 2004.
Friday, September 29: Richard G. Sedlak, COL, USA, OIC–Medical Radiological Advisory Team, AFRRI: Acute radiation syndrome, Part I (Medical Effects of Ionizing Radiation).
Monday, September 25: Tal Brosh Nissimov, MD, Head of Radiological and Nuclear Section, CBRN Medicine Branch, Medicine Corps, IDF, Israel: 1. Medical preparedness for radiological terrorism in Israel—Current status and vision for the future: 2. Approach to inhalation exposure of soldiers to depleted uranium aerosols.
Friday, September 22: Daniel F. Flynn, MD, Department of Radiation Oncology, Holy Family Hospital, Methuen, Mass.: Medical management of casualties of nuclear terrorism.
Friday, September 15: Joel S. Greenberger, MD, Claude Worthington Benedum Professor and Chairman, Department of Radiation Oncology, University of Pittsburgh Medical Center/Co-Director of the Lung Cancer Center of the University of Pittsburgh Cancer Institute, Pittsburgh, Penna.: Antioxidant radioprotective gene therapy. Related information:
- Antipocyte differentiation in Sod2^-/- and Sod2^+/+ murine stromal cells is associated with low antioxidant pools. Exp Hematol. 33:1201–1208, 2005.
- Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small cell lung carcinoma treated with three-dimensional conformal radiotherapy with or without concurrent chemotherapy. Clin Lung Cancer. 7:100–107, 2005.
- Protection of esophageal multi-lineage progenitors of squamous epithelium (stem cells) from ionizing irradiation by manganese superoxide dismutase-plasmid/liposome MnSOD-PL) gene therapy. In Vivo 19:965–974, 2005.
Friday, September 8: Michael Perkins, PhD, Research Scientist, Henry M. Jackson Foundation (Radiation Countermeasures Program, AFRRI): Radioprotection studies of the chlorobenzyl sulfone analogue ON01210: In vitro studies. Related information:
- Ligninolytic and non-ligninolytic mineralization of trinitrotoluene (TNT) by several white rot basidiomycetes. Bioremediation, 9:77–85, 2005.
Friday, September 1: Natalia I. Ossetrova, PhD, Research Associate (National Research Council–The National Academies), Scientific Research Department, AFRRI: Use of discriminant analysis for the study of early-response multiple protein biomarkers of radiation exposure using non-human primate whole-body radiation mode. Related information:
- High-sensitivity blood-based detection of breast cancer by diagnostic proteomics. J Proteome Res. 5:1906–1915, 2006.
- Ultra-high sensitivity multi-photon detection imaging in proteomics analyses. Proteomics 5:2322–2330, 2005.
- Ultra-sensitive immunoassays using multi-photon-detection in diagnostic proteomics of blood. J Proteome Res. 4:2375–2387, 2005.
Friday, July 14 (Lecture Room C, USUHS): Zhanat Carr, MD, PhD, medical officer, REMPAN coordinator, Radiation and Environment Health Unit, Department of Protection of the Human Environment, World Health Organization (WHO) headquarters, Geneva, Switzerland: An overview of the WHO radiation health program and its role in the preparedness and response to radiation emergency. Related information:
- World Health Organization's International Radon Project. J Toxicol Environ Health A. 69:759–769, 2006.
- Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys. 61:842–850, 2005.
- Malignant neoplasms after radiation therapy for peptic ulcer. Radiat Res. 157:668–677, 2002
Friday, July 7: Charles A. Salter, LTC, USA, Scientific Research Department, AFRRI: Psychological factors of ionizing radiation (from Medical Effects of Ionizing Radiation Course). Related information:
- Early-response biological dosimetry: Recommended countermeasure enhancements for mass-casualty radiological incidents and terrorism. Health Phys. 89:494–504, 2005.
- Psychological effects of nuclear and radiological warfare. Mil Med. 166:17–18, 2001.
Friday, June 23: Nannette C. Parra, CPT, USA, Chief, Medicine Division, Veterinary Sciences Department, AFRRI: Occupational safety and zoonotic diseases of laboratory animals. Related information:
- Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol. Life Sci. 78:2099–2104, 2006.
Friday, June 9: Louis Peńa, MS, PhD, Medical Department, Brookhaven National Laboratory, Upton, NY: Radiation protection by synthetic growth factor analogs. Related information:
- Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo. Int J Mol Med. 17:833–839, 2006.
- Multidomain synthetic peptide B2A2 synergistically enhances BMP-2 in vitro. J Bone Miner Res. 20:693–703, 2005.
Friday, June 2: Michael Joiner, MA, PhD, program leader, Radiation Biology, Karmanos Cancer Institute, and professor, Department of Radiation Oncology, Wayne State University: Low intensity radiation: Is cell kill the most important effect? Related information:
- Low-dose hyper-radiosensitivity is not caused by a failire to recognize DNA double-strand breaks. Radiat Res. 165:516–524, 2006.
- Toxicity from radiation in breast cancer. Cancer Treat Res. 128:65–109, 2006.
- Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol. 81:751–758, 2005.
Friday, May 26 (DoD only): Christine A. Ege, MAJ, USA, Veterinary Sciences Department, AFRRI: Animal care and use within the Armed Forces Radiobiology Research Institute. Related information:
- Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol. Life Sci. 78:2099–2104, 2006.
Friday, May 19 (DoD only): Mang Xiao, MD, Scientific Research Department, AFRRI: Radioprotection of human hematopoietic CD34+ cells by 5-AED is dependent on the NFkB survival signal pathway. Related information:
- Analysis of primitive CD34– and CD34+ hematopoietic cells from adults: Gain and loss of CD34 antigent by undifferentiated cells are closely linked to proliferative status in culture. Stem Cells 22:556–569, 2004.
- Jun blockade of erythropoiesis: Role for repression of GATA-1 by HERP2. Mol Cell Biol. 24:7779–7794, 2004.
Friday, May 12: Nannette C. Parra, CPT, USA, Veterinary Sciences Department, AFRRI: Serum lipid concentrations and severity of disease in ⁶⁰Co gamma-irradiated Sus scrofa domestica and Macaca mulatta. Related information:
- Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol. Life Sci. 78:2099–2104, 2006.
Friday, May 5: Theodor A. Zainal, LT, USN, Scientific Research Department, AFRRI: Radiation biology (from Medical Effects of Ionizing Radiation Course). Related information:
- Caloric restriction of rhesus monkeys lowers oxidative damage in skeletal muscle. FASEB J. 14:1825–1836, 2000.
- Localization of 4-hydroxy-2-nonenal-modified proteins in kidney following iron overload. Free Radic Biol Med. 26:1181–1193, 1999.
Friday, April 21 (DoD only): Vijay K. Singh, PhD, Scientific Research Department, AFRRI: Modulation of cytokine expression in mice by radiation countermeasures. Related information:
- Induction of cytokines by radioprotective tocopherol analogs. Exp Mol Pathol. 81(1):55–61, 2006.
- Role of cytokines in growth factors in radioprotection. Exp Mol Pathol. 78:156–169, 2005.
- Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. Immunopharmacol Immunotoxicol. 27:521–534, 2005.
Friday, April 14: Robert Woodruff, LCDR, USN, AFRRI: Nuclear/radiological threat assessment.
Friday, April 7: Prakash Hande, PhD, associate professor, National University of Singapore (NUS): Telomere Dysfunction and DNA Repair Deficiency: Markers of sensitivity to mutagens and carcinogens. Related information:
- Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev. 18:1144–1153, 2004.
- Involvement of Mammalian Mus81 in genome integrity and tumor suppression. Science 304:1822–1826, 2004.
- Telomere dysfunction and chromosome instability in tumorigenesis, NUS website, telomere projects
Friday, March 31 (DoD only): Michael O. Shoemaker, PhD, Scientific Research Department, AFRRI: Real-time radiotelemetric monitoring of NHPs during gamma-photon irradiation. Related information:
- Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without ⁶⁰Co gamma-photon irradiation. J Med Microbiol. 54:1157–1162, 2005.
- Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in ⁶⁰Co-gamma-photon-irradiated and sham-irradiated mice. J Antimicrob Chemother. 56:1074–1080, 2005.
Friday, March 24 (DoD only): David E. McClain, PhD, Military Metals Program Manager, Scientific Research Department, AFRRI: Potential for chelator-linked magnetic nanoparticle decorporation of internalized radionuclides. Related information:
- Embedded weapons-grade tungsten alloy shrapnel rapidly induces metastatic high-grade rhabdomyosarcomas in F344 rats. Environ Health Perspect. 113:729–734, 2005.
- Health effects of embedded depleted uranium. Mil Med. 167:117–119, 2002.
Friday, March 17: John F. Kalinich, PhD, Scientific Research Department, AFRRI: Health effects of embedded tungsten alloy fragments. Related information:
- Depleted uranium-uranyl chloride induces apoptosis in mouse J774 macrophages. Toxicology 179:104–114, 2002.
- Health effects of embedded depleted uranium. Mil Med. 167:117–119, 2002.
Friday, March 10 (DoD only): Gregory L. King, PhD, Scientific Research Department, AFRRI: Probiotics and radiation: Old directions and new. Related information:
- Nuclear, biological, and chemical combined injuries and countermeasures on the battlefield. Mil Med. 167:95–97, 2002.
Friday, March 3: G. David Ledney, PhD, Radiation Infection Treatment Program Manager, Scientific Research Department, AFRRI: Ciprofloxacin in polymicrobial sepsis of irradiated non-human primates (Macaca mulatta): A pilot study. Related information:
- Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in ⁶⁰Co-gamma-photon-irradiated and sham-irradiated mice. J Antimicrob Chemother. 56:1074–1080, 2005.
- Management of postirradiation infection: lessons learned from animal models. Mil Med. 169:194–197, 2004.
Friday, February 24: Marcy B. Grace, PhD, Scientific Research Department, AFRRI: Validation models for gene expression biomarkers of radiation exposure and dose. Related information:
- Human in vivo radiation-induced biomarkers. Cancer Res. 64:6368–6371, 2004.
- Development and assessment of a quantitative reverse transcription-PCR assay for simultaneous measurement of four amplicons. Clinical Chem. 49:1467–1475, 2003.
Friday, February 17: William F. Blakely, PhD, Biological Dosimetry Project Manager, Scientific Research Department, AFRRI: Enhancements of medical countermeasures for nuclear and radiological events—A biodosimetry perspective. Related information:
- Early-response biological dosimetry—recommended countermeasure enhancements for mass-casualty radiological incidents and terrorism. Health Phys. 89:494–504, 2005.
- Premature chromosome condensation in human resting peripheral blood lymphocytes for chromosome aberration analysis using specific whole-chromosome DNA hybridization probes. Methods Mol Biol. 291:49–57, 2005.
Friday, January 27: Michael R. Landauer, PhD, Scientific Research Department, AFRRI: Evaluation of genistein as a radiation countermeasure. Related information:
- Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol. 23:379–385, 2003.
- Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 189:1–20, 2003.
Friday, January 20: Thomas B. Elliott, PhD, Scientific Research Department, AFRRI: Pharmacokinetics and pharmacodynamics of fluoroquinolones in irradiated mice. Related information:
- Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without ⁶⁰Co gamma-photon irradiation. J Med Microbiol. 54:1157–1162, 2005.
- Minimum inhibitory concentrations of herbal essential oils and monolaurin for gram-positive and gram-negative bacteria. Mol Cell Biochem. 272:29–34, 2005.
Friday, January 13: Venkataraman Srinivasan, PhD, Scientific Research Department, AFRRI: Radiation and countermeasure agents in mice: Evaluation of two promising candidates. Related information:
- Radioprotection by N-palmitoylated nonapeptide of human interleukin-1beta. Peptides 26:413–418, 2005.
- Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharm Pharmacol. 56:1118–1125, 2004.
Friday, January 6: Joel Lowy, PhD, Scientific Research Department, AFRRI: Virus infection and radiation: Apoptosis caspase activity. Related information:
- A multidisciplinary approach to teach responses to weapons of mass destruction and terrorism using combined simulation modalities. J Clin Anesth. 16:152–158, 2004.
- Active and inactive influenza virus induction of tumor necrosis factor-alpha and nitric oxide in J774.1 murine macrophages: modulation by interferon-gamma and failure to induce apoptosis. Virus Res. 97:117–126, 2003.

TOP OF PAGE


USU home \| USU site index \| MHS \| WRNMMC \| NSAB			AFRRI home \| Text version \| A–Z Index
No FEAR Act \| Privacy/Security notice \| USU webmaster			Disclaimer \| Copyright \| Site map

	USA.GOV	HTML \| CSS